Topic
Pharmaceuticals
991 published works
Product Perspective: Complex Tort & Product Law
Gilead Tenofovir Cases: California Supreme Court Rejects Duty to Innovate or Accelerate Development of Alternatives to Non-Defective Products
By Hilda Akopyan, Malea Casillas, Magda Patitsas
Can a pharmaceutical manufacturer face liability for failing to bring an allegedly safer drug to market sooner, even when the drug it already sells is not defective? In Gilead Tenofovir…
SALT Shaker
Hard to swallow: Ohio Supreme Court holds a drug maker’s CAT base is what it actually receives, not the list price
On September 22, 2026, the Supreme Court of Ohio unanimously held in Perrigo Sales Corp. v. Harris, Slip Opinion No. 2026-Ohio-3648, that the amount a prescription-drug manufacturer “realized” for purposes…
Big Molecule Watch
Alvotech and Advanz Pharma Announce Submission for Proposed Eylea 8 mg Biosimilar
By Alice Yoon
On October 14, 2026, Alvotech and Advanz Pharma announced the submission of a European regulatory application for AVT29, a proposed biosimilar to Eylea® 8 mg (aflibercept 114.3 mg/mL), marketed as…
Dentons Insights
Dentons Bratislava Life Sciences Alert: Act on Reimbursement of Medicines (in Slovak)
By Dentons
Slovak Republic: The Slovak National Council has approved a comprehensive ministerial amendment to the Act on the Reimbursement of Medicines.
Dentons Insights
Dentons Bratislava Life Sciences Alert: Act on Reimbursement of Medicines
By Dentons
Slovak Republic: The Slovak National Council has approved a comprehensive ministerial amendment to the Act on the Reimbursement of Medicines.
Truth on the Market
The World Wants Cures. America Gets the Check.
By Alden Abbott
Everyone wants the next medical breakthrough. Few want the bill. The United States pays a disproportionate share of the cost of pharmaceutical innovation, while other wealthy countries hold down medicine…
Global Policy Watch
Germany Reviews a New Pharma “Location Clause” (Standortklausel) for Pricing & Reimbursement Incentives – Improvement or Worsening for the Pharmaceutical Industry?
By Dr. Dr. Adem Koyuncu, Maximilian Aretz
Hot off the press, yesterday evening, 29 September 2026, the German Government’s expert committee presented the eagerly awaited proposal for a new "location clause" (Standortklausel) to incentivize pharmaceutical R&D and…
Big Molecule Watch
Biocon’s Pertuzumab Biosimilar Receives Positive CHMP Opinion Under EMA’s Tailored Clinical Approach
By Yoko Bian
On September 22, 2026, Biocon Biologics Limited (“Biocon”) announced that the European Medicines Agency’s (“EMA”) Committee for Medicinal Products for Human Use (“CHMP”) issued a positive opinion recommending marketing authorization…
Spicy IP
Call for Submissions:’Impact of the Intersection of Innovation and Access by the EU-India FTA'(Deadline: October 20, 2026)
By SpicyIP
Image from here The Innovation Brief, NLU Delhi, is inviting blog post submissions on the ‘Impact of the Intersection of Innovation and Access by the EU-India FTA’. The last date…
Neal, Gerber & Eisenberg LLP
ACI’s 2nd Annual Forum on Pharma & Biotech Patent Litigation USA & Canada
The life sciences industry continues to navigate significant legal and business developments across intellectual property, regulatory compliance, commercialization, and emerging technologies. Companies face increasing pressure to protect innovation while adapting…